Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $6.88M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost increased by 44.5% year-over-year, from $4.76M to $6.88M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a 139.6% compound annual growth rate (CAGR), from $87K to $6.88M.